Lenvatinib Plus I-125 Seed Brachytherapy vs. Lenvatinib for TACE-refractory HCC

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Lenvatinib Plus I-125 Seed Brachytherapy vs. Lenvatinib for TACE-refractory HCC	Digestive System Diseases, Digestive System Neoplasms, Liver Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, adenocarcinoma, carcinoma, epithelial neoplasm, hepatocellular carcinoma, liver disorder, neoplasm	Recruiting	Phase 3	2022-11-08		NCT05608213

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Second Affiliated Hospital of Guangzhou Medical University	70

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
The second Affiliated Hospital of Guangzhou Medical University	Guangzhou	China	26

Clinical trials